Case Details
- Citation: [2023] SGHC 360
- Court: High Court of the Republic of Singapore
- Date: 2023-12-29
- Judges: Dedar Singh Gill J
- Plaintiff/Applicant: Millennium Pharmaceuticals, Inc and Johnson & Johnson Pte Ltd
- Defendant/Respondent: Zyfas Medical Co (sued as a firm)
- Legal Areas: Intellectual Property — Patents and inventions
- Statutes Referenced: Health Products Act
- Cases Cited: [2020] SGHC 28, [2023] SGHC 360
- Judgment Length: 200 pages, 50,498 words
Summary
This case involves a dispute over two patents related to the manufacture of bortezomib, a drug used for the treatment of multiple myeloma and mantle cell lymphoma. The plaintiffs, Millennium Pharmaceuticals, Inc and Johnson & Johnson Pte Ltd, allege that the defendant, Zyfas Medical Co, infringed their patents by supplying a generic version of bortezomib in Singapore. The defendant denies infringement and further contends that the patents are invalid for lack of novelty, lack of inventive step, and insufficiency of particulars.
The two patents at issue are Singapore Publication No. SG 151322 ("SG 322") and Singapore Application No. SG 10201600029P ("SG 29P"). SG 322 claims to improve the Matteson Homologation process for the synthesis of bortezomib by using a coordinating ether solvent with low miscibility in water. SG 29P claims to teach the use of convergent synthesis for the large-scale manufacture of bortezomib.
What Were the Facts of This Case?
The first plaintiff, Millennium Pharmaceuticals, Inc, is the registered proprietor of the two patents. The second plaintiff, Johnson & Johnson Pte Ltd, is alleged to be an exclusive licensee of the first plaintiff and the distributor of the "brand-name" bortezomib drug, Velcade, in Singapore.
The defendant, Zyfas Medical Co, is a Singapore-registered partnership that carries on business in the wholesale and distribution of pharmaceutical products. In February 2018, the defendant applied to the Health Sciences Authority (HSA) for approval to import, market, and distribute a generic version of bortezomib, "MYBORTE POWDER FOR SOLUTION FOR INJECTION 3.5MG/VIAL", which is manufactured by Dr Reddy's Laboratories Limited (DRL). On 5 July 2019, the HSA approved the registration of the defendant's generic bortezomib product under Registration No. SIN15736P.
The plaintiffs allege that the defendant's generic bortezomib product infringes their patents, while the defendant denies infringement and contends that the patents are invalid.
What Were the Key Legal Issues?
The key legal issues in this case are:
1. Whether the second plaintiff, Johnson & Johnson Pte Ltd, has standing to commence the patent infringement proceedings.
2. Whether SG 322 and SG 29P are valid patents.
3. Whether the defendant's generic bortezomib product infringes SG 322.
How Did the Court Analyse the Issues?
The court first examined the standing of the second plaintiff, Johnson & Johnson Pte Ltd, to commence the patent infringement proceedings. The court found that the second plaintiff was an exclusive licensee of the first plaintiff in respect of the patents and the distributor of the "brand-name" bortezomib drug in Singapore, and therefore had the necessary standing to bring the infringement claims.
The court then analyzed the validity of the two patents, SG 322 and SG 29P, in detail. For SG 322, the court examined the novelty, inventive step, and sufficiency of disclosure requirements. The court found that claim 1 of SG 322 was novel and sufficiently disclosed, but lacked an inventive step over the prior art.
For SG 29P, the court examined the novelty and inventive step requirements. The court found that claim 1 of SG 29P was not novel, as it was anticipated by the prior art.
Finally, the court analyzed the issue of infringement of SG 322. The court found that the plaintiffs had shown a substantial likelihood that the defendant's generic bortezomib product was made using the process taught in SG 322, and that the burden of proof had shifted to the defendant. However, the court ultimately concluded that the plaintiffs had not proven the defendant's alleged infringement of SG 322.
What Was the Outcome?
The court held that SG 322 is valid but not infringed, and SG 29P is invalid for lack of inventive step. The court dismissed the plaintiffs' claims for patent infringement and the defendant's counterclaim for partial or full revocation of the patents.
Why Does This Case Matter?
This case provides important guidance on the legal principles and requirements for the validity and infringement of process patents in the pharmaceutical industry. The court's detailed analysis of the novelty, inventive step, and sufficiency of disclosure requirements for the two patents, as well as the burden of proof in patent infringement cases, will be valuable precedents for future disputes involving pharmaceutical process patents.
The case also highlights the complex technical and legal issues that can arise in the context of generic drug competition, where the manufacturer of the generic product must navigate the patent landscape to bring its product to market. The court's careful consideration of the technical evidence and the application of the relevant legal principles will be of interest to both patent holders and generic drug manufacturers in the pharmaceutical sector.
Legislation Referenced
- Health Products Act
Cases Cited
- [2020] SGHC 28
- [2023] SGHC 360
Source Documents
This article analyses [2023] SGHC 360 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.